就斯鲁利单抗而言,ASTRUM系列研究正全面布局肺癌领域,其为ES-SCLC和晚期sqNSCLC患者带来了突破性疗效获益的同时,在LS-SCLC(ASTRUM-020研究)和nsqNSCLC(ASTRUM-002研究)领域亦积极展开探索并取得一定成果。此外,斯鲁利单抗在美国已启动一项对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验(ASTRIDE研究),有望实现...
IMbrella A扩展研究结果:IMpower133研究中接受阿替利珠单抗治疗的ES-SCLC患者的5年生存率 摘要号 OA01.04 英文标题 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study ...
Clinical Evaluation of ES-NSCLC in Japan EP: 2.Determining Resectability in ES-NSCLC EP: 3.Molecular Testing in Early-Stage NSCLC EP: 4.Testing for EGFR in NSCLC Worldwide EP: 5.Standard of Care for EGFR+ ES-NSCLC EP: 6.Adjuvant Approaches in EGFR+ NSCLC EP: 7.Unprecedented Results ...
NSCLC是一种多基因、多因素导致的疾病,对肺癌组织分泌至肺泡中的物质进行检测,探究一种灵敏度、特异度相对较高的有临床应用价值的生物标记物对ES⁃NSCLC的诊断尤为重要。HGF、TGF⁃β1为肺癌组织直接分泌的分泌性蛋白。HGF可以活化c⁃met蛋白,参与信号通路的激活,从而导致肿瘤细胞的增殖、迁徙以及刺激血管再生[6...
卢凯华教授:斯鲁利单抗在ES-SCLC和sqNSCLC中均获得了非常成功的结果,那么我们自然也会期待其在非鳞癌当中也能拥有不错的表现。但是,如果我们仅仅是进行免疫联合化疗的尝试,那么这与未来的发展还是存在一定的差距的,因为无论是抗血管生成药物,还是抗体药物偶联物(ADC)类药物(包括靶向Trop2的Dato-DXd等),这些药物都在...
第三代EGFR-TKI是EGFR突变非小细胞肺癌(NSCLC)脑转移患者的标准一线治疗。脑部放疗用于该人群的临床价值、人群选择和最佳时机仍存在争议。本课题组既往研究表明,针对接受第三代EGFR-TKI治疗的EGFR突变NSCLC脑转移患者,早期脑部立体定向放疗(eSRT)用于脑部寡转移人群可带来生存获益。然而,针对基线脑部寡转移EGFR突变NSCLC患...
3118: CNN vs manual segmentation for ES-NSCLC: performance assessment and current pitfallsdoi:10.1016/S0167-8140(24)03179-7Federico MastroleoStefania VolpeFrancesca BottaMattia ZaffaroniMaria Giulia VinciniMatteo FerranteLisa RinaldiGaia Piperno
Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Liver cancer (HCC), & Adva
Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Liver cancer (HCC), & Adva
Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Liver cancer (HCC), & Adva